Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Antibodies to glutamic acid decarboxylase (GAD), the major pathway for the synthesis of c-aminobutyric acid(GABA) in humans, are found at elevated levels in a subgroup of patients with chronic epilepsy. To test whether the antibodies were associated with changes in cortical GABA levels we used magnetic resonance spectroscopy. Four patients with epilepsy and high serum GAD antibody levels (107-6,200 units/ml) and 10 healthy controls were recruited. A 3T GABA-optimized spectrum was obtained from a reproducible voxel in the cortex. Compared to the control group, the patient group had significantly lower GABA concentrations within the cortex. Demonstration of an association between high serum GAD antibodies and low cortical GABA levels in patients with epilepsy suggests that GAD antibodies are, at least, a marker of a specific disease process and support a role for immune-mediated GABAergic dysfunction.

Original publication

DOI

10.1111/j.1528-1167.2010.02644.x

Type

Journal article

Journal

Epilepsia

Publication Date

09/2010

Volume

51

Pages

1898 - 1901

Keywords

Adult, Aged, Autoantibodies, Biomarkers, Cerebral Cortex, Epilepsy, Female, Glutamate Decarboxylase, Glutamates, Humans, Magnetic Resonance Spectroscopy, Male, Middle Aged, gamma-Aminobutyric Acid